This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

RECTOGESIC-product-image
rectogesic-introduction
rectogesic-introduction

RECTOGESIC®

Introduction

RECTOGESIC 4 mg/g Rectal Ointment is indicated in adults for relief of pain associated with chronic anal fissure.

Click here for prescribing information and adverse event reporting.

What is RECTOGESIC ointment used for?

RECTOGESIC relieves the pain associated with chronic anal fissure. RECTOGESIC should be used following conservative treatment failure for symptoms of anal fissure.1

signs and symptoms of OIC

Reliable

  • The ONLY treatment licensed in the UK for pain relief in chronic anal fissure,1,2 relieving pain of over 3 million fissures worldwide since launch.3
  • A uniform, quality assured formulation.

Effective

  • In Phase III clinical trials RECTOGESIC has been shown to improve the average daily pain intensity associated with chronic anal fissure compared with placebo.1
  • RECTOGESIC significantly lowered pain scores vs placebo.4

Tolerated

  • In Phase III trials, less than 6% of patients discontinued treatment due to headaches.4
  • Headache can be treated with simple analgesics such as paracetamol and is reversible on discontinuation of treatment.1

Average:

  • References

    1. RECTOGESIC® (glyceryl trinitrate) Summary of Product Characteristics

    2. British National Formulary Online. Available at: https://bnf.nice.org.uk/treatment-summary/anal-fissure.html Last accessed: March 2024.

    3. Kyowa Kirin Data on File - DOF-UK-074-Rectogesic.

    4. Berry SM, Barish CF, Bhandari R, et al. Nitroglycerin 0.4% ointment vs placebo in the treatment of pain resulting from chronic anal fissure: a randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013 Jul 1;13:106.

    M-RCG-UK-11-23-0004 March 2024